Canary Wharf's bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by Genomics England to relocate to the development.
Lantern Pharma, a pharma company which uses artificial intelligence to develop shelved oncology drugs has joined Genomics England’s groundbreaking industry partnership.
South Korea is to build a comprehensive database of genetic and biometric data from 10 million people, in a bid to boost its pharma and biotech industry.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.